We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Lag3.6

Larch Arabinogalactan Research

Mostly mechanism / observationalHigh safety

4 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Larch Arabinogalactan studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from medium-quality randomised trials published 2010–2023 with a typical study size of 75 participants.

Based on 4 studies · 2 RCTs · 319 total participants

Confidence

Low

By outcome

Immune supportEnhanced antibody response to vaccines and a modest reduction in common-cold incidence in small RCTs · 4-12 weeks
Mostly mechanism / observational3 studies
Safety profile
Too few graded studies2 studies

Steady research

1 study in the last 5 years

201020162023

1RCTn=75 · small study2013

Larch arabinogalactan at 1.5 g/day significantly increased the IgG antibody response to tetanus vaccine compared to placebo.

Udani JK. · J Am Coll Nutr (2013)

1.5 g/day significantly increased tetanus IgG response versus placebo at day 60 (p = 0.008)
Neither dose raised influenza IgM/IgG significantly versus placebo
No clinically or statistically significant serious adverse events

View source

2RCTn=199 · medium study2013

Over 12 weeks, larch arabinogalactan 4.5 g/day significantly reduced the number of participants affected by a common cold versus placebo.

Riede L, Grube B, Gruenwald J. · Curr Med Res Opin (2013)

Significantly fewer participants affected by a cold with arabinogalactan (p = 0.038 FAS; p = 0.033 per-protocol)
Cold incidence reduction was borderline in the full analysis set (p = 0.055) but significant per-protocol (p = 0.040)
Well tolerated with no significant differences in adverse events

View source

3Pilotn=45 · small study2010

Larch arabinogalactan 4.5 g/day increased the IgG antibody response to the 23-valent pneumococcal vaccine versus placebo in two antibody subtypes.

Udani JK, Singh BB, Barrett ML, Singh VJ. · Nutr J (2010)

Significantly greater IgG response in pneumococcal subtypes 18C and 23F at days 51 and 72 (p < 0.05)
Other subtypes trended higher but did not reach significance
No effect on salivary IgA, white blood cell count, cytokines, or complement

View source

4In Vitro2023

In an in-vitro fermentation model, arabinogalactan lowered fermentation pH, increased short-chain fatty acids, and enriched Bifidobacterium and Lactobacillus.

Liu F, Chen S, Dong D, et al. · Food Funct (2023)

Arabinogalactan-containing biscuits had the lowest estimated glycemic index of the fibers tested
Decreased fermentation pH and increased short-chain fatty acid levels
Increased abundance of Bifidobacterium and Lactobacillus in both diabetic and healthy fecal microbiota

View source

View in Research Library

Larch Arabinogalactan Research

Mostly mechanism / observational

Immunomodulatory effects of ResistAid: A randomized, double-blind, placebo-controlled, multidose study.

Larch arabinogalactan effects on reducing incidence of upper respiratory infections.

Proprietary arabinogalactan extract increases antibody response to the pneumonia vaccine: a randomized, double-blind, placebo-controlled, pilot study in healthy volunteers.

Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.